Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Summary

MALVERN, Pa., Sept. 16, 2021 – Baudax Bio, a pharmaceutical company focused on acute care innovations, announced that CEO Gerri Henwood will participate in a virtual fireside chat during the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Sept. 22, 2021, at 1:15 p.m. ET. A live webcast will be accessible on Baudax Bio's investor page, with a replay available for 30 days post-event. Baudax Bio's primary product, ANJESO, is the first 24-hour intravenous COX-2 preferential NSAID used for moderate to severe pain management, alongside a pipeline of other novel pharmaceutical assets.

News Market Reaction – BXRX

-1.66%

-1.66% Session move

In the trading session that priced this news, BXRX declined 1.66%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 1:15 p.m. ET.

A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

FAQ

When will Baudax Bio's CEO participate in the Oppenheimer Summit?

Baudax Bio's CEO, Gerri Henwood, will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 1:15 p.m. ET.

How can I watch the Baudax Bio fireside chat?

The live webcast of the Baudax Bio fireside chat will be available on the 'Presentations' page of their investor website.

What is ANJESO, and how is it used?

ANJESO is Baudax Bio's first product, a 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain.

What other products are in Baudax Bio's pipeline?

Besides ANJESO, Baudax Bio has a pipeline that includes two novel neuromuscular blocking agents and a proprietary chemical reversal agent.

Will a replay of the Baudax Bio fireside chat be available?

Yes, a replay of the fireside chat will be available on the Baudax Bio website for 30 days following the event.